Drug Profile
NIP 520
Latest Information Update: 31 Jan 2008
Price :
$50
*
At a glance
- Originator Nissan Chemical Industries
- Class Antiasthmatics
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 24 Apr 2007 No development reported - Phase-I for Asthma in United Kingdom (unspecified route)
- 03 Feb 2000 Phase-I clinical trials for Asthma in United Kingdom (Unknown route)
- 14 Sep 1999 New profile